Filing Details
- Accession Number:
- 0000939767-17-000045
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-03-24 19:41:11
- Reporting Period:
- 2017-03-22
- Filing Date:
- 2017-03-24
- Accepted Time:
- 2017-03-24 19:41:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 939767 | Exelixis Inc. | EXEL | Services-Commercial Physical & Biological Research (8731) | 043257395 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1599803 | Jeffrey Hessekiel | C/O Exelixis, Inc. 210 E. Grand Ave. South San Francisco CA 94080 | Evp And General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-03-22 | 55,000 | $1.70 | 301,617 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-03-22 | 23,787 | $20.54 | 277,830 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-03-16 | 3,000 | $0.00 | 274,830 | No | 5 | G | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 5 | G | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option (right to buy) | Disposition | 2017-03-22 | 55,000 | $0.00 | 55,000 | $1.70 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 145,000 | 2015-07-20 | 2021-09-18 | No | 4 | M | Direct |
Footnotes
- Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.53 to $20.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
- The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016.
Billionaire Hedge Funds
